VERACYTE, INC. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Veracyte, Inc. on April 22, 2015, regarding a material definitive agreement entered into on the same date. The Company is a Delaware corporation headquartered in South San Francisco, California.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of common stock.
- Shares Issued: 4,907,975 shares of common stock.
- Price Per Share: $8.15.
- Gross Proceeds: Approximately $40 million.
- Placement Agent Fees: Approximately $2.5 million (Piper Jaffray & Co. as lead agent; William Blair & Company, L.L.C. as co-agent).
- Net Proceeds: Approximately $37.3 million after deducting fees and expenses.
- Use of Proceeds: Research and development, commercialization, working capital, and general corporate purposes.
Note: This filing does not provide historical revenue, profit, cash flow, margin, or debt metrics. It focuses solely on the capital raise event.
Material Changes and Agreements
The Company entered into a Securities Purchase Agreement with certain accredited investors. The transaction is expected to close on or about April 27, 2015, subject to customary closing conditions. Additionally, a Registration Rights Agreement was executed, requiring the Company to file a registration statement with the SEC within 30 days of the closing to cover the resale of the shares.
Outlook, Risks, and Contingencies
The securities sold in this private placement were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933. The filing notes that the securities have not been registered under the Securities Act of 1933 or applicable state securities laws and may not be offered or sold in the United States absent registration or an exemption. No specific forward-looking guidance or risk factors beyond standard regulatory disclosures were detailed in this specific text.
Key Facts for Investor Verification
- Verify the closing of the private placement on or about April 27, 2015.
- Confirm the filing of the registration statement for resale of shares within 30 days of closing.
- Monitor the actual deployment of the approximately $37.3 million in net proceeds toward R&D and commercialization.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Registration Rights Agreement (Exhibit 10.2) for specific covenants and limitations.